Fingerprint
Dive into the research topics of 'Unveiling abrocitinib: A thorough examination of the 2022 USFDA-approved treatment for atopic dermatitis (AD)'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Unveiling abrocitinib: A thorough examination of the 2022 USFDA-approved treatment for atopic dermatitis (AD)
Daniela Bermeo Grajales, Nermala Sewdat, Ryan Leo, Supratik Kar
Research output: Contribution to journal › Review article › peer-review
6
Scopus
citations